Abstract
Busulfan is an alkylating agent that can be used in the treatment and control of chronic myeloblastic leukemia. Milk thistle seed extract of dried herb in 1 to 4 % silymarin is a powerful antioxidant flavonoid. In this study, busulfan and bone marrow suppression were used to assess whether the effect of silymarin can suppress cell death, or at least reduce it. Forty-two Wistar male rats were fed with a standard diet, divided into six groups of eight rats and treated as follows. Group 1—control group (received nothing). Group 2—control silymarin, 175 mg/kg/day silymarin was gavage for 14 days. Group 3—anemic control group, 20 mg/kg/day busulfan was injected intraperitoneally (i.p.) for 14 days. Group 4—experimental group 1 received 20 mg/kg/day busulfan (i.p.) for 14 days, and after 2 weeks, 175 mg/kg/day silymarin was gavage for 14 days. Group 5—two groups received 20 mg/kg/day dose busulfan (i.p.) for 14 days, and after 2 weeks, 250 mg/kg/day silymarin was gavage for 14 days. Group 6—three groups received 20 mg/kg/day dose busulfan (i.p.) for 14 days, and after 2 weeks, 325 mg/kg/day silymarin was gavage for 14 days. Hematological and bone marrow parameters were measured using standard routine procedures. The results showed that after 2 weeks, in the group that had received busulfan with healthy controls, leukocyte parameters were influenced more by the drug similar to the control group. In samples of bone marrow cells after treatment with silymarin, a slight difference between the groups was observed, but the cells are promyelocyte, myelocyte, and metamyelocyte, and band width in the control group of healthy controls and patient groups treated with silymarin was different. Decrease in bone marrow cells of control group was significantly different from the control group treated with silymarin. The effects of silymarin on bone marrow cells and peripheral blood leukocytes lead to reduced cell death, reducing oxidative stress and protecting cells against apoptosis, and the mechanisms, probably due to antioxidant properties, are unknown.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bhatia N, Zhao J, Wolf DM, Agarwal R (1999) Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 147(1/2):77–84
Branford S, Hughes TP (2010) Practical considerations for monitoring patients with chronic myeloid leukemia. Semin Hematol 47(4):327–334
Carini R, Comoglio A, Albano E, Poli G (1992) Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by thesilybin-phospholipid complex IdB 1016. Biochem Pharmacol 43(10):2111–2115
Galton DA (1969) Chemotherapy of chronic myelocytic leukemia. Semin Hematol 6:323–343
Gazák R, Svobodová A, Psotová J, Sedmera P, Prikrylová V, Walterová D, Kren V (2004) Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 12(21):5677–5687
Gibson FM, Andrews CM, Diamanti P, Rizzo S, Macharia G, Gordon-Smith EC, Williams T, Turton J (2003) A new model of busulphan-induced chronic bone marrow aplasia in the female BALB/c mouse. Int J Exp Pathol 84:31–48
Guest I, Uetrecht J (2000) Drugs toxic to the bone marrow that target the stromal cells. Immuno Pharmacol 46(2):103–112
Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, Banerjee SK, Handa SS (2000) Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 7(1):21–24
Kang JS, Jeon YJ, Park SK, Yang KH, Kim HM (2004) Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1 beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol 67:175–181
Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 1011:168–176
Katiyar SK, Mantena SK, Meeran SM (2011) Silymarin protects epidermal keratinocytes from ultraviolet radiation-induced apoptosis and DNA damage by nucleotide excision repair mechanism. PLoS One 6, e21410
Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Jr Gansler TS, Holl JF, Frei E (2003) Cancer medicine. 6th ed. BC Decker Inc, Bookshelf ID: NBK12354
Lettéron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, Larrey D, Pessayre D (1990) Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol 39(12):2027–2034
Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM (2003) Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37:336–339
Madani H, Ahmadi Mahmoodabady N, Vahdati A (2006) Effects of hydroalcoholic extract of Anethumgraveolens (Dill) on plasma glucose and lipid levels in diabetes induced rats. Iranian J Diabetes Lipid 5:109–116
Mereish KA, Bunner DL, Ragland DR, Creasia DA (1991) Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharmaceut Res 8(2):273–277
Mira L, Silva M, Manso CF (1994) Scavenging of reactive oxygen species by silibin dihemisuccinate. Biochem Pharmacol 48:753–759
Morley A, Blake J (1974) An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood 44:49–56
Mulero M, Romeu M, Giralt M, Folch J, Nogués MR, Fortuño A, Sureda FX, Linares V, Cabré M, Paternáin JL, Mallol J (2006) Oxidative stress-related markers and langerhans cells in a hairless rat model exposed to UV radiation. J Toxicol Environ Health A 69:1371–1385
Perez-Victoria JM, Perez-Victoria FJ, Conseil G, Maitrejean M, Comte G, Barron D, Di Pietro A, Castanys S, Gamarro F (2001) High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoproteinlike transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. Antimicrob Agents Chemother 45(2):439–446
Pinnell SR (2003) Cutaneous photo damage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48:1–19
Sajedianfard J, Behroozi Z, Nazifi S (2014) The effects of a hydroalcoholic extract of silymarin on serum lipids profiles in streptozotocin induced diabetic rats. Comp Clin Pathol 23(3):779–785
Singer CR, McDonald GA, Douglas AS (1984) Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion. Br J Haematol 57:309–313
Sokal JE (1973) Current concepts in the treatment of chronic myelocytic leukemia. Annu Rev Med 24:281–288
Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L (2003) Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol rich diets. Pharmacol Res 47:17–26
Vengerovskii AI, Khazanov VA, Eskina KA, Vasilyev KY (2007) Effects of silymarin (hepatoprotector) and succinic acid (bioenergy regulator) on metabolic disorders in experimental diabetes mellitus. Bull Exp Biol Med 144:58–61
Wang S, Chen B, Sun C (2000) Regulation effect of curcumin on blood lipids and antioxidation in hyperlipidemia rats. Wei Sheng Yan Jiu 29:240–242
Zi X, Feyes DK, Agarwal R (1998) Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin dependent kinases and associated cyclins. Clin Cancer Res 4(4):1055–1064
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Honarmand, M., Sajedianfard, J. & Nazifi, S. Hematological and bone marrow parameters in busulfan-treated rats: effects of silymarin extract. Comp Clin Pathol 24, 1515–1520 (2015). https://doi.org/10.1007/s00580-015-2109-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-015-2109-9